# 2026-20441: Too-Much-Oxygen Detector Joins Pulse Ox with Easier FDA Rules

2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-10-06, effective 2026-10-06; PRIA reads it as touching household money (as of 2026-10-13).

- Canonical: https://policyrisk.com/federal-register/2026-20441
- As of: 2026-10-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20441
- Title: Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 63491
- Published: 2026-10-06
- Effective: 2026-10-06
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-13

## In one line

Too-Much-Oxygen Detector Joins Pulse Ox with Easier FDA Rules

## Summary

The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.

## Abstract

The Food and Drug Administration (FDA) is classifying the hyperoxia monitoring device adjunct to pulse oximetry into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the hyperoxia monitoring device adjunct to pulse oximetry. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Device reclassified to Class II — easier access: benefit, medium. The FDA has classified the hyperoxia monitoring device adjunct to pulse oximetry as Class II (special controls), effective October 6, 2026 (classification applicable October 12, 2023). FDA says this places the device in a lower device class than automatic Class III, which reduces regulatory burdens…
- Manufacturers must meet specific special controls: mixed, medium. Manufacturers who market this device must follow Class II special controls and submit a premarket notification under section 510(k). The special controls explicitly require clinical performance testing; human factors/usability testing; electromagnetic compatibility and electrical safety testing; bi…
- Required labeling to protect patients and guide use: benefit, low. Labeling for these devices must include cleaning and disinfection instructions, a summary of clinical performance testing, a warning not to over-rely on device output without confirming with arterial blood gas values, and instructions to monitor oxygen delivery and the patient’s clinical/cardiovasc…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20441 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/06/2026-20441/medical-devices-cardiovascular-devices-classification-of-the-hyperoxia-monitoring-device-adjunct-to)
- [2026-20441 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-06/pdf/2026-20441.pdf)

## Related
- [Previous: 2026-20440, Medical Devices; General and Plastic Surgery Devices; Classification of the Foc…](https://policyrisk.com/federal-register/2026-20440)
- [Next: 2026-20443, Medical Devices; Immunology and Microbiology Devices; Classification of the Hig…](https://policyrisk.com/federal-register/2026-20443)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20441 (as of 2026-10-13).
